KIT and thymic carcinoma: An analysis of the mutational status of druggable targets such as EGFR, c-KIT, KRAS, BRAF, PDGFR, HER2, and c-MET in thymic epithelial tumors did not reveal any targetable mutations except infrequent c-KIT mutations in thymic carcinoma [28].